How should the response to osteoporosis treatment be evaluated?;Cómo valorar la respuesta al tratamiento de la osteoporosis

Revista Clinica Espanola

Volumn 208, Issue 5, 2008, Pages 247-250

  Olmos Martinez J M ^a   Martinez Garcia J ^a   Gonzalez Macias J ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Bone mineral density; Bone remodeling markers; Fractures; Osteoporosis; Treatment

Indexed keywords

BONE ATROPHY; BONE DENSITY; BONE MASS; BONE REMODELING; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; DRUG TREATMENT FAILURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; MORBIDITY; MORTALITY; NOTE; OSTEOPOROSIS; PREVENTIVE MEDICINE; TREATMENT OUTCOME;

EID: 44349174426     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1157/13119919     Document Type: Article

References (19)

1. Lewiecki EM. Nonresponders to osteoporosis therapy. J Clin Densitom. 2003;6:307-14.
2. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006;119 (4 Suppl 1):S25-31.
3. Shoback D. Update in osteoporosis and metabolic bone disorders. J Clin Endocrinol Metab. 2007;92:747-53.
4. Marcus R, Wong M, Heath H, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev. 2002;23:16-37.
5. Cefalu CA. Is bone mineral density predictive of fracture risk reduction? Curr Med Res Opin. 2004;20:341-9.
6. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, et al. Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study. J Bone Miner Res. 2006;21:1565-70.
7. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clinic Proc. 2005;80:379-88.
8. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson D, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-92.
9. Wasnick RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-6.
10. Hochberg MC, Ros PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum. 1999;42:1246-54.
11. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005;20:971-6.
12. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate: the Fracture Intervention Trial. Osteoporos Int. 2005;16:842-8.
13. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas P. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004;19:394-401.
14. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255-61.
15. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250-8.
16. Roux C, Garnero P, Thomas T, Sabatier JP, Orcel P, Audran M. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. J Bone Spine. 2005;72:26-31.
17. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry. Misleading changes and regression to the mean. JAMA. 2000;283:1318-21.
18. Bonnick SL. Monitoring osteoporosis therapy with bone densitometry: a vital tool or regression toward mediocrity? J Clin Endocrinol Metab. 2000;85:3493-5.
19. Srivastava AK, Vliet EL, Lewiecki EM, Maricic M, Abdelmalek A, Gluck O, et al. Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin. 2005;21:1015-26.